Sandra Christensen
Nurse Practitioner · Seattle, WANPI 1376606699
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $149,574 of the $243,635 with a category attached, or 61.4%. Novo Nordisk accounts for 68.7% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $85,469, more than ten times the $1,121 reported in 2019. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $595.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$167K
- Lilly USA, LLC$59K
- Boehringer Ingelheim$13K
- Eli Lilly$5K
- Abbott$110
- Currax Pharmaceuticals LLC$53
- plus $34 from 1 others
What the payments were for
- Consulting fees$35,00614%
- Speaking & faculty fees$149,57461%
- Travel & lodging$49,07120%
- Food & beverage$9,9844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 226 | $167,360 |
| Lilly USA, LLC | 146 | $58,674 |
| Boehringer Ingelheim | 13 | $12,751 |
| Eli Lilly | 21 | $4,653 |
| Abbott | 1 | $110 |
| Currax Pharmaceuticals LLC | 1 | $53 |
| Amgen | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$243,635 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 19 | $18,672 |
| Fluoxetine Hcl | 12 | $163 |
| Trazodone Hcl | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $58,674 | $18,67219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Seattle
- Olga VoloshinaSeattle$279K
- Sonia GlennieSeattle$78K
- Lia Duque Estrada de BarrosSeattle$43K
- Vanessa DunleavySeattle$34K
- Lyne Schaefer AlfonseSeattle$18K
- Amy PerezSeattle$14K
- Mei Kuen Erica ToSeattle$13K
- Omeid HeidariSeattle$13K
- Cayla AlexanderSeattle$13K
- Adrianne MaurerSeattle$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.